The study findings could help predict which patients will develop resistance to PARP inhibitors and allow doctors to alter treatment at the earliest possible opportunity.

The Institute of Cancer Research, London, has been recognised with a highly prestigious Queen’s Anniversary Prize for its world-leading research in cancer drug discovery.

Scientists have developed a new highly sensitive blood test to deliver precision medicine to women with BRCA mutations who have breast or ovarian cancer.